USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
    10.
    发明申请
    USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS 有权
    使用有效标记来优化抗人PD-1抗体对癌症的治疗效果

    公开(公告)号:US20110123550A1

    公开(公告)日:2011-05-26

    申请号:US13001875

    申请日:2009-07-03

    摘要: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.

    摘要翻译: 本发明的目的是提供一种能够更有效地制备用于抗癌治疗的抗人PD-1抗体的方法,用于估计或优化其治疗功效的方法,以及可用于 方法。 本发明能够通过测量在施用后多于血液中的几种功效标记物的一定水平的变化来选择将来能够预期抗人PD-1抗体的治疗功效的癌症患者的选择 与施用初始剂量之前的抗人PD-1抗体的初始剂量或剂量相比较,并且提供了用于抗癌治疗的抗人PD-1抗体的新处方。